全球乳房復发评分测试市场

预计到 2030 年，全球乳房復发评分测试市场规模将达到 4.141 亿美元

全球乳癌復发评分测试市场规模预计在2024年为2.49亿美元，到2030年将达到4.141亿美元，在分析期间（2024-2030年）的复合年增长率为8.8%。本报告分析的乳癌细分领域之一—1期乳癌，预计其复合年增长率为10.3%，到分析期结束时规模将达到1.584亿美元。 2期乳癌细分领域在分析期间的复合年增长率预计为9.5%。

美国市场规模估计为 6,790 万美元，而中国市场预计复合年增长率为 13.9%

美国乳癌復发评分检测市场规模预计在2024年达到6,790万美元。作为世界第二大经济体，中国预计到2030年市场规模将达到9,150万美元，在2024-2030年的分析期间内，复合年增长率为13.9%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为4.4%和8.5%。在欧洲，预计德国市场的复合年增长率为5.9%。

全球乳房復发评分测试市场－主要趋势与驱动因素摘要

基因组分析将如何彻底改变乳癌的预后和治疗计画？

乳房復发评分测试与 Oncotype DX 等基因组检测结合使用，大大改变了临床医生评估乳癌復发风险和做出有关辅助性治疗的重要决策的方式。该测试评估特定癌症相关基因组（通常为 21 个基因）的表达，以创建个人化復发评分，该评分可估计初次治疗后 10 年内远处癌症復发的可能性。与严重依赖临床和病理特征（例如肿瘤大小、淋巴结转移和荷尔蒙受体状态）的传统预后工具不同，乳腺復发评分测试提供了肿瘤生物学的分子洞察。这使肿瘤学家能够将患者分为低风险、中风险和高风险类别，并相应地制定治疗计划。例如，復发评分低的患者通常可以放弃化疗，避免严重的副作用而不会影响存活结果。这是乳癌治疗的一个重要模式转移，朝着精准肿瘤学迈进，强调个人化治疗而不是一刀切的方案。 TAILORx 和 RxPONDER 等里程碑式临床试验所累积的临床证据已检验该检测的临床效用，并增强了医生和患者对其结果的信心。随着此检测效用的认可度不断提高，它越来越多地被纳入早期荷尔蒙受体阳性、HER2阴性乳癌的标准治疗方案中，从而改善了临床疗效，并提高了患者满意度和生活品质。这项检测也顺应了价值导向医疗的转变，能够制定更具成本效益的治疗方案，并减少不必要的治疗性介入。

临床指引和报销政策发挥什么作用？

乳房復发评分测试日益被纳入临床指南和报销框架，这对加速该测试在全球的普及起到了关键作用。美国临床肿瘤学会 (ASCO)、美国国家综合癌症网络 (NCCN) 和圣加仑国际专家共识等权威组织已将该测试纳入激素受体阳性、HER2 阴性乳癌的正式管理指南。这些认可赋予了该测试强大的临床可信度，并鼓励世界各地的肿瘤学家将其作为常规诊断工具。同时，许多公共和私人保险公司，尤其是美国、加拿大和一些欧洲国家的保险公司，都核准了该测试的报销，承认其在改善患者预后和减少过度治疗方面的长期价值。报销政策对测试利用率有直接影响，核准的诊断测试很可能会被广泛采用，尤其是在医疗保健系统集中的国家。此外，保险覆盖范围的扩大也方便了医疗资源匮乏的人群接受检测，使精准肿瘤学更加公平。经济评估显示，该检测可以显着节省不必要的化疗、住院治疗和治疗相关副作用的长期管理费用，从而指南政策决策。在新兴市场，随着当地监管机构对临床数据和成本效益报告的评估，将此类基因组检测纳入公共卫生策略的进程缓慢但稳定。此外，製药和诊断公司正在积极与卫生署和付款方合作，以建立检测采用的途径。医疗需求、政策支持和成本控制目标的整合巩固了乳癌復发评分测试在现代癌症治疗中的地位。

技术进步是否提高了测试的准确性和全球可近性？

分子诊断技术的进步极大地提高了乳房復发评分测试的准确性、扩充性和可及性。该测试最初仅在中心实验室进行，且週转时间较长，而新版本得益于简化的检体处理、更快的基因表现分析和更强大的演算法，可确保准确计算復发风险。 RNA 萃取技术和即时PCR平台的改进使得即使少量切片检查样本也能获得可重复的结果，使该测试在临床环境中更加通用。技术创新也扩展了可用的检体类型，包括芯针活检和福马林固定石蜡包埋组织，进一步简化了测试管理的物流。随着基因组资料库的增加和机器学习被纳入肿瘤学研究，未来对復发评分的增强可能还会纳入其他数据，例如患者人口统计数据、合併症和免疫特征，以实现更个人化的风险评估。在可近性方面，诊断开发公司与区域病理实验室之间的伙伴关係正在实现分散式检查模式。数位病理学和云端基础的数据传输系统也促进了远距会诊和同行评审，弥合了都市区癌症中心之间的差距。检测设备的小型化和自动化基因组分析的出现，使得规模较小的医疗机构能够提供高精度的检测。总而言之，这些技术创新将在确保不同患者群体检测结果的一致性以及在全球范围内扩大检测覆盖范围方面发挥关键作用。

推动全球乳癌復发评分测试扩展的关键市场因素有哪些？

乳癌復发评分测试市场的成长受到多种因素的推动，这些因素与癌症治疗通讯协定的改变、技术的成熟度以及患者期望的转变直接相关。其中一个关键驱动因素是全球乳癌发生率的上升，这正在迅速提高人们的认知度和早期诊断水平，尤其是在年轻人口和开发中地区。这催生了对能够个人化治疗并避免过度治疗带来的身心和经济负担的工具的强烈需求。同时，早期乳癌逐渐转向以化疗为重点的逐渐减量治疗，使得復发评分测试成为关键的决策辅助工具。医疗保健提供者越来越多地寻求检验。此外，越来越多知情的患者群体要求治疗的透明度和精准性，这促使肿瘤学家将基因组检测作为标准治疗，而不仅仅是一项建议。在医疗服务提供者方面，多学科肿瘤委员会和基于价值的医疗保健模式正在进一步推动检测的利用，以优化资源利用率和疗效。另一个关键的市场力量是诊断公司积极地透过策略伙伴关係、宣传宣传活动和临床医生教育计画扩大其全球影响力。这些努力正在产生重大影响，尤其是在亚太和拉丁美洲地区，这些地区的本地检验研究和监管核准正在蓬勃发展。最后，将基因组学整合到常规癌症治疗（从生物标记引导治疗到风险分层）的更广泛动力，为復发评分检测的持续增长创造了肥沃的环境。这些相互关联的因素，包括流行病学、临床、经济和技术因素，共同推动了全球乳房復发评分检测市场保持强劲的上升趋势。

部分

适应症（1期乳癌适应症、2期乳癌适应症、雌激素受体阳性癌症适应症、淋巴结阴性癌症适应症）、最终用户（医院最终用户、专科癌症中心最终用户、其他最终用户）

受访公司范例

• Abbott Laboratories
• Agendia
• Biocartis
• Bio-Rad Laboratories
• Caris Life Sciences
• Epic Sciences
• Exact Sciences
• Foundation Medicine
• Guardant Health
• Hologic Inc.
• Illumina Inc.
• Myriad Genetics
• NanoString Technologies
• Natera
• OncoDNA
• Oncomatryx
• Qiagen
• Roche Diagnostics
• Thermo Fisher Scientific
• Varian Medical Systems

人工智慧集成

我们正在利用可操作的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 比赛

Global Breast Recurrence Score Test Market to Reach US$414.1 Million by 2030

The global market for Breast Recurrence Score Test estimated at US$249.0 Million in the year 2024, is expected to reach US$414.1 Million by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Stage 1 Breast Cancer Indication, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$158.4 Million by the end of the analysis period. Growth in the Stage 2 Breast Cancer Indication segment is estimated at 9.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$67.9 Million While China is Forecast to Grow at 13.9% CAGR

The Breast Recurrence Score Test market in the U.S. is estimated at US$67.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$91.5 Million by the year 2030 trailing a CAGR of 13.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Global Breast Recurrence Score Test Market - Key Trends & Drivers Summarized

How Is Genomic Profiling Revolutionizing Breast Cancer Prognosis and Treatment Planning?

The Breast Recurrence Score Test, most commonly associated with genomic assays like Oncotype DX, has dramatically transformed how clinicians assess the risk of breast cancer recurrence and make critical decisions about adjuvant therapy. This test evaluates the expression of a specific panel of cancer-related genes-typically 21 genes-to produce a personalized recurrence score that estimates the likelihood of distant cancer recurrence within ten years of initial treatment. Unlike traditional prognostic tools that rely heavily on clinical and pathological features such as tumor size, lymph node involvement, and hormone receptor status, the Breast Recurrence Score Test provides a molecular-level insight into tumor biology. This enables oncologists to better stratify patients into low, intermediate, or high-risk categories, tailoring treatment plans accordingly. For example, patients with a low recurrence score can often forgo chemotherapy, thus avoiding its considerable side effects without compromising survival outcomes. This has marked a significant paradigm shift in breast cancer care, moving toward precision oncology that emphasizes individualized treatment over one-size-fits-all protocols. The growing body of clinical evidence from landmark trials such as TAILORx and RxPONDER has validated the clinical utility of the test, boosting physician and patient confidence in its results. As awareness of the test’s capabilities grows, it is increasingly being integrated into standard care protocols for early-stage, hormone receptor-positive, HER2-negative breast cancer. The result is not just improved clinical outcomes, but enhanced patient satisfaction and quality of life. The test also aligns with the shift toward value-based healthcare, by enabling more cost-effective treatment planning and reducing unnecessary therapeutic interventions.

What Role Are Clinical Guidelines and Reimbursement Policies Playing in Driving Adoption?

The increasing integration of the Breast Recurrence Score Test into clinical guidelines and insurance reimbursement frameworks has played a critical role in accelerating its global adoption. Esteemed bodies such as the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), and the St. Gallen International Expert Consensus have incorporated the test into their formal guidelines for managing hormone receptor-positive, HER2-negative breast cancer. These endorsements have lent strong clinical credibility to the test, encouraging oncologists across the globe to adopt it as a routine diagnostic tool. In tandem, many public and private insurers-particularly in the U.S., Canada, and parts of Europe-have approved reimbursement for the test, recognizing its long-term value in improving patient outcomes and minimizing overtreatment. Reimbursement policies have a direct influence on test utilization, especially in countries with centralized healthcare systems, where approved diagnostic tests are more likely to be widely adopted. Moreover, expanding insurance coverage has facilitated access to the test for underserved populations, making precision oncology more equitable. Policy decisions have also been guided by economic evaluations that show the test can significantly reduce the costs associated with unnecessary chemotherapy, hospital stays, and long-term management of treatment-related side effects. In emerging markets, the inclusion of such genomic assays in public health strategies is slower but steadily increasing, as local regulatory bodies assess clinical data and cost-effectiveness reports. Additionally, pharmaceutical companies and diagnostic firms are actively engaging with health ministries and payers to establish pathways for test adoption. The alignment of medical necessity, policy support, and cost-containment objectives has solidified the Breast Recurrence Score Test’s place in contemporary cancer care.

Are Technological Advancements Enhancing Test Accuracy and Global Accessibility?

The evolution of molecular diagnostics technology has greatly enhanced the accuracy, scalability, and accessibility of Breast Recurrence Score Tests. Originally processed only in centralized labs with long turnaround times, newer iterations benefit from streamlined sample processing, faster gene expression analysis, and increasingly robust algorithms that ensure precise recurrence risk calculation. The improvement in RNA extraction techniques and real-time PCR platforms has led to more reproducible results, even from small biopsy samples, thus making the test more versatile across clinical scenarios. Technological innovation has also expanded the range of usable specimen types, including core needle biopsies and formalin-fixed paraffin-embedded tissues, further simplifying the logistics of test administration. As genomic databases grow and machine learning becomes more integrated into oncology research, future enhancements in recurrence scoring may also incorporate additional data such as patient demographics, comorbidities, and immune profiles for even more individualized risk assessment. In terms of accessibility, partnerships between diagnostic developers and regional pathology labs are enabling decentralized testing models, allowing quicker turnaround times and lowering the barrier to adoption in lower-resource settings. Digital pathology and cloud-based data transfer systems also facilitate remote consultation and peer review, bridging the gap between urban and rural cancer centers. The miniaturization of lab instrumentation and the advent of automated genomic analysis are making it feasible for smaller healthcare facilities to offer these tests with high accuracy. Collectively, these innovations not only ensure consistent performance across patient populations but also play a crucial role in scaling up test availability globally-making personalized breast cancer care a tangible reality for more women, regardless of geographic location.

What Key Market Forces Are Driving the Expansion of Breast Recurrence Score Testing Worldwide?

The growth in the Breast Recurrence Score Test market is driven by several factors directly linked to changing cancer care protocols, technological maturity, and shifting patient expectations. A major driver is the global rise in breast cancer incidence, particularly among younger populations and in developing regions where awareness and early diagnosis are rapidly improving. This has created a strong demand for tools that can personalize treatment and avoid the physical, emotional, and financial toll of overtreatment. Concurrently, the shift toward de-escalation of therapy-especially chemotherapy-in early-stage breast cancer has positioned recurrence score tests as critical decision-making aids. Healthcare providers are increasingly seeking diagnostic tools that provide actionable insights, and the Breast Recurrence Score Test fits that role by delivering clinically validated, easy-to-interpret results that directly influence treatment pathways. Moreover, a growing population of well-informed patients is demanding transparency and precision in their care, leading oncologists to adopt genomic testing not just as a recommendation, but as a standard of care. On the provider side, multi-disciplinary tumor boards and value-based healthcare models are further promoting test usage to optimize resource utilization and outcomes. Another important market force is the active role of diagnostic companies in expanding their global footprint through strategic partnerships, awareness campaigns, and clinician education programs. These efforts are particularly impactful in Asia-Pacific and Latin American regions, where local validation studies and regulatory approvals are gaining momentum. Finally, the broader movement toward integrating genomics into routine oncology practice-from biomarker-based treatment to risk stratification-has created a fertile environment for the sustained growth of recurrence score testing. These interconnected factors-epidemiological, clinical, economic, and technological-are collectively ensuring that the global market for Breast Recurrence Score Tests remains on a robust upward trajectory.

SCOPE OF STUDY:

The report analyzes the Breast Recurrence Score Test market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication, Lymph-Node-Negative Cancer Indication); End-Use (Hospitals End-Use, Specialty Cancer Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Agendia
• Biocartis
• Bio-Rad Laboratories
• Caris Life Sciences
• Epic Sciences
• Exact Sciences
• Foundation Medicine
• Guardant Health
• Hologic Inc.
• Illumina Inc.
• Myriad Genetics
• NanoString Technologies
• Natera
• OncoDNA
• Oncomatryx
• Qiagen
• Roche Diagnostics
• Thermo Fisher Scientific
• Varian Medical Systems

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Breast Recurrence Score Test - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Precision Oncology Throws the Spotlight on Breast Recurrence Score Tests as Prognostic Tools
  • Shift Toward Personalized Breast Cancer Treatment Spurs Growth in Genomic Recurrence Risk Testing
  • Here's How Clinical Guidelines Are Driving Adoption of Recurrence Score Tests to Inform Chemotherapy Decisions
  • Expanding Use in Early-Stage HR-Positive, HER2-Negative Breast Cancer Strengthens the Business Case for Risk Stratification
  • Increased Physician and Patient Awareness Fuels Demand for Evidence-Based, Genomic-Driven Treatment Planning
  • Here's the Story: How TAILORx and RxPONDER Trial Results Are Validating Clinical Utility Across Demographics
  • Integration with Electronic Health Records and Oncology Decision Support Systems Enhances Workflow Efficiency
  • Growing Emphasis on Avoiding Overtreatment Supports the Economic Value Proposition of Recurrence Score Testing
  • Global Expansion of Molecular Pathology Labs Enables Broader Access in Developed and Emerging Markets
  • Rising Incidence of Breast Cancer Worldwide Expands the Addressable Market for Genomic Recurrence Assays
  • Innovation in Liquid Biopsy and Multi-Gene Panels May Disrupt or Complement Current Recurrence Score Test Models
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Breast Recurrence Score Test Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Breast Recurrence Score Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Stage 1 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Stage 1 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Stage 1 Breast Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Stage 2 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Stage 2 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Stage 2 Breast Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Estrogen-Receptor-Positive Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Estrogen-Receptor-Positive Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Estrogen-Receptor-Positive Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Lymph-Node-Negative Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Lymph-Node-Negative Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Lymph-Node-Negative Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Specialty Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Specialty Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Specialty Cancer Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• JAPAN
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CHINA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: China 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: China 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• EUROPE
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Breast Recurrence Score Test by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• FRANCE
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: France 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: France 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• GERMANY
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Breast Recurrence Score Test by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Australia 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Australia 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• INDIA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 116: India Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: India 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 119: India Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: India 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: South Korea 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: South Korea 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Breast Recurrence Score Test by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Argentina 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Argentina 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Brazil 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Brazil 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Mexico 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Mexico 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Rest of Latin America 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Rest of Latin America 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Breast Recurrence Score Test by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Iran 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Iran 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Israel 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Israel 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Saudi Arabia 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Saudi Arabia 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: UAE 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: UAE 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Middle East 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Middle East 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AFRICA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Africa 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Africa 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION